Ondansetron
Brand names: Zofran, Ondansetron 4mg
Ondansetron is a 5-HT3 receptor antagonist antiemetic used to prevent and treat post-operative nausea and vomiting and nausea and vomiting associated with chemotherapy and radiotherapy.
Adult dose
Dose adjustments
SPC posology, verbatim: 'Patients with Renal impairment: No alteration of daily dosage or frequency of dosing, or route of administration are required.'
SPC posology, verbatim: 'Patients with Hepatic impairment: Clearance of Ondansetron is significantly reduced and serum half life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8mg should not be exceeded.'
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
US labelling (FDA)
Reference — US labelling, may differ from UKSee full prescribing information for the recommended dosage in adults and pediatrics (2) Patients with severe hepatic impairment: do not exceed a total daily dose of 8 mg ( 2.2 , 8.6 ) 2.1 Dosage The recommended dosage regimens for adult and pediatric patients are described in Table 1 and Table 2, respectively. Corresponding doses of ondansetron tablets may be used interchangeably. Table 1: Adult Recommended Dosage Regimen for Prevention of Nausea and Vomiting Indication Dosage Regimen Highly Emetogenic Cancer Chemotherapy A single 24 mg dose administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin greater than or equal to 50 mg/m 2 …
Source: US FDA prescribing information (openFDA / DailyMed), label dated 2024-04-24. Accessed 2026-06-12. US dosing and indications can differ from UK practice — use UK sources for prescribing decisions.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- Concomitant use with apomorphine
- NOT listed as a contraindication in this SPC but a section 4.4 instruction — 'Avoid ondansetron in patients with congenital QT syndrome.'
- Excipient caution — this syrup contains sodium benzoate (E211), 'which may increase jaundice (yellowing of the skin and eyes) in new born babies (up to 4 weeks old)', and xylitol (E967), which may have a laxative effect
Side effects
- Very common: headache
- Common: sensation of warmth or flushing; constipation
- Uncommon: seizures; movement disorders including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia; arrhythmias; chest pain with or without ST segment depression; bradycardia; hypotension; hiccups; asymptomatic increases in liver function tests
- Rare: immediate hypersensitivity reactions, sometimes severe, including anaphylaxis; QTc prolongation including Torsades de Pointes; dizziness during rapid IV administration; transient visual disturbances such as blurred vision, predominantly during IV administration
- Very rare: transient blindness predominantly during intravenous administration — 'The majority of the blindness cases reported resolved within 20 minutes.'
- Frequency unknown: myocardial ischaemia — 'In some patients, especially in the case of intravenous administration, symptoms appeared immediately after administration of ondansetron.'
- Post-marketing: serotonin syndrome (altered mental status, autonomic instability, neuromuscular abnormalities) with concomitant serotonergic drugs including SSRIs and SNRIs
- 'The adverse event profiles in children and adolescents were comparable to that seen in adults.'
Monitoring
- QT interval and cardiac risk — section 4.4: ondansetron prolongs the QT interval in a dose-dependent manner and post-marketing Torsades de Pointes has been reported; administer with caution to patients who have or may develop QTc prolongation, including those with electrolyte abnormalities, congestive heart failure, bradyarrhythmias, or taking other medicinal products that prolong QT or cause electrolyte abnormalities.
- 'Hypokalemia and hypomagnesaemia should be corrected prior to ondansetron administration.'
- Alert patients to the signs and symptoms of myocardial ischaemia.
- Monitor patients with signs of subacute intestinal obstruction after administration, as ondansetron increases large bowel transit time.
- After adenotonsillar surgery, follow patients carefully — 'prevention of nausea and vomiting with ondansetron may mask occult bleeding'.
- Observe the patient appropriately if a serotonergic drug is clinically warranted alongside ondansetron.
- Watch for respiratory events and treat them symptomatically — section 4.4 notes clinicians should 'pay particular attention to them as precursors of hypersensitivity reactions'; hypersensitivity has occurred in patients who reacted to other selective 5HT3 receptor antagonists.
- Paediatric: 'Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.'
Clinical monograph
How it works
It selectively blocks 5-HT3 (serotonin) receptors peripherally on vagal afferents and centrally in the chemoreceptor trigger zone, interrupting the emetic reflex.
Prescribing in practice
- It prolongs the QT interval, so observe dose limits and use with caution or avoid alongside other QT-prolonging drugs or uncorrected electrolyte disturbance.
- Constipation and headache are common adverse effects.
- In pregnancy (for example hyperemesis gravidarum) use only after weighing risks and benefits, as first-trimester use has been associated with a small increase in the risk of cleft palate.
Monitoring
Consider ECG and check electrolytes (including potassium and magnesium) in patients at risk of QT prolongation, and monitor bowel function.
Counselling the patient
- This medicine can cause constipation and headache — let us know if these become troublesome.
- Tell your doctor about any heart rhythm problems or other medicines you take, as some can affect your heartbeat.
- Seek urgent help if you notice palpitations, fainting or an irregular heartbeat.
Evidence & guidelines
Widely guideline-recommended for chemotherapy-induced and post-operative nausea and vomiting; MHRA advice on QT prolongation and first-trimester use.
Reference: NICE; MHRA Ondansetron Safety Update 2013; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021